N-(3-(5-(3-Hydroxybenzoyl)thiophene-2-yl)phenyl)benzenesulfonamide

ID: ALA3629438

PubChem CID: 122194303

Max Phase: Preclinical

Molecular Formula: C23H17NO4S2

Molecular Weight: 435.53

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  O=C(c1cccc(O)c1)c1ccc(-c2cccc(NS(=O)(=O)c3ccccc3)c2)s1

Standard InChI:  InChI=1S/C23H17NO4S2/c25-19-9-5-7-17(15-19)23(26)22-13-12-21(29-22)16-6-4-8-18(14-16)24-30(27,28)20-10-2-1-3-11-20/h1-15,24-25H

Standard InChI Key:  ZWJIJXZDRXHGET-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
    4.6017  -12.1261    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.4020  -12.0971    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    4.0271  -11.0728    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.6837  -10.7794    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.2990   -0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2990    0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    1.5000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2990    0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2990   -0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000   -1.5000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3383    1.3500    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.0031   -3.0008    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3039   -3.7494    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4469   -5.2297    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    2.9152   -5.5365    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.6607   -4.2349    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6532   -3.1236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0351   -3.6026    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.5304   -6.9054    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7488   -8.1798    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4649   -9.4979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9644   -9.5368    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.7478   -8.2576    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.0317   -6.9396    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6208  -13.3786    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3396  -14.6952    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5588  -15.9759    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0592  -15.9401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3405  -14.6236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1212  -13.3428    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10  5  1  0
  6 11  1  0
 10 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 13  2  0
 12 18  2  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 19  1  0
 15 19  1  0
 21  4  1  0
  4  2  1  0
  2 25  1  0
 25 26  2  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  2  0
 30 25  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA3629438

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 435.53

Molecular Weight (Monoisotopic): 435.0599

AlogP: 5.15

#Rotatable Bonds: 6

Polar Surface Area: 83.47

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 7.77

CX Basic pKa: ┄

CX LogP: 5.17

CX LogD: 5.03

Aromatic Rings: 4

Heavy Atoms: 30

QED Weighted: 0.41

Np Likeness Score: -1.07

References

1. Abdelsamie AS, Bey E, Gargano EM, van Koppen CJ, Empting M, Frotscher M..  (2015)  Towards the evaluation in an animal disease model: Fluorinated 17β-HSD1 inhibitors showing strong activity towards both the human and the rat enzyme.,  103  [PMID:26322835] [10.1016/j.ejmech.2015.08.030]

2. Abdelsamie AS, Herath S, Biskupek Y, Börger C, Siebenbürger L, Salah M, Scheuer C, Marchais-Oberwinkler S, Frotscher M, Pohlemann T, Menger MD, Hartmann RW, Laschke MW, van Koppen CJ..  (2019)  Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing.,  62  (3): [PMID:30645111] [10.1021/acs.jmedchem.8b01493]

Source

Source(1):

• Scientific Literature